The BioHub - by Avetix

In this episode of The BioHub Podcast, Max sits down with Cameron Pitt, Co-Founder and COO of Quanta Therapeutics.

Cameron's career has taken him from academic research at Stanford and UCSF, to venture investing at Versant Ventures and Sofinnova Investments, before helping form and build Quanta Therapeutics from the ground up.

Quanta is focused on one of the biggest challenges in oncology: targeting RAS-driven cancers. Using a novel approach designed to restore control of RAS signalling, the company is developing therapies aimed at addressing a broad range of RAS-driven tumours.

In this conversation, we discuss Cameron's transition from academia to venture capital and company building, the science behind Quanta, the realities of building a biotech company, and how the team is thinking about growth and fundraising in today's market.

In this episode of The BioHub Podcast, Max sits down with Geert Kersten, Chairman and CEO of CEL-SCI Corporation.

Geert has led CEL-SCI for nearly three decades, overseeing the development of the company's lead immunotherapy candidate, Multikine, and navigating one of the longest and most challenging journeys in biotech.

In this conversation, we discuss the realities of building a biotech company over the long term, the persistence required to advance innovative therapies, and Geert's perspective on today's biotech market.

We also explore CEL-SCI's recent clinical progress, the company's long-term vision, and the lessons Geert has learned from spending almost 30 years at the helm of a public biotech company.

In this episode of The BioHub Podcast, Max sits down with Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals.

Leonard is a seasoned entrepreneur and pharmaceutical executive who has spent decades building, scaling, and commercializing healthcare companies. Throughout his career, he has founded multiple successful businesses, led major transactions, and helped bring innovative therapies to patients across a range of therapeutic areas.

In this conversation, we discuss Leonard's journey as a serial entrepreneur, the lessons he's learned from building companies from the ground up, and the importance of combining strong science with commercial strategy.

We also explore the evolution of Citius Pharmaceuticals, the company's recent milestones, the challenges of navigating today's biotech market, and Leonard's advice for the next generation of biotech founders and leaders.

In this episode of The BioHub Podcast, Max sits down with Derek Small, Founder and Managing Director of Luson Bioventures.

Over the past two decades, Derek has built a reputation as one of biotech's leading venture creators, founding and leading multiple companies across neuroscience and CNS drug development. Through Luson, he has helped launch, finance, and scale businesses from inception, raising more than $1 billion in capital along the way.

In this conversation, we discuss the differences between venture creation and traditional venture capital, why neuroscience remains one of the most exciting areas in biotech, and what it takes to build successful companies through changing market cycles.

We also explore capital efficiency, company building in today's environment, and the lessons Derek has learned from founding and leading biotech companies over the last twenty years.

Today's guest is Edward Ahn, CEO of MEDIPOST Inc., a biotechnology company at the forefront of regenerative medicine and stem cell therapeutics. Based in Cambridge, Massachusetts, MEDIPOST is leading the global development of innovative cell therapies designed to address inflammation-driven degenerative diseases, with a mission to move beyond symptom management and toward true disease modification.
Edward leads MEDIPOST's U.S. operations and global expansion efforts for CARTISTEM®, the world's first approved allogeneic stem cell therapy derived from umbilical cord blood. Since its approval in South Korea, CARTISTEM has been used to treat more than 30,000 patients, and under Edward's leadership the company is now advancing late-stage clinical development in the United States, with one of the most ambitious regenerative medicine programs in orthopedics today.
What makes Edward's perspective particularly interesting is his focus on the practical realities of turning breakthrough science into scalable healthcare solutions. He has championed a strategy that combines clinical development, manufacturing infrastructure, regulatory execution, and long-term commercialization planning from day one. That vision has included building a North American presence, forming strategic manufacturing partnerships, and creating the operational foundation required to bring advanced cell therapies to patients around the world.
As regenerative medicine moves from promise to reality, Edward has become a leading voice on how biotechnology companies can successfully navigate the path from scientific innovation to global commercialization. His work sits at the intersection of stem cell science, healthcare innovation, manufacturing strategy, and venture-backed growth—areas that will define the next generation of medicine.